Clinical Study

Testing The Effect Of Adding Abiraterone Acetate And Enzalutamide To Metastatic Hormone Refractory Prostate Cancer, When Compared To Enzalutamide Alone

Posted Date: Aug 17, 2017

  • Investigator: Nilesh Patil
  • Co-Investigator: Nilesh Patil
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Drug

The purpose of this study is to compare the effects, good and/or bad, of abiraterone, prednisone and enzalutamide with enzalutamide alone on patients and their cancer to find out which is better. Doctors are uncertain about which way is the best way to tr

Criteria:

To Be Eligible To Participate, Patients Must Have Prostate Cancer That Has Spread And Has Not Responded To Hormonal Therapy.

Keywords:

Abiraterone, Metastatic Prostate Cancer, Enzalutamide, Cancer, A031201

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.